UBS/CALL/ELI LILLY & CO/640/0.1/20.12.24 | Delayed Deutsche Boerse AG 06:14:31 27/06/2024 pm IST | ||
| 27.15 EUR | +1.72% |
|
| Current month | +37.01% | ||
| 1 month | +39.16% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 27.15 | +1.72% |
| 26/24/26 | 26.69 | -1.04% |
| 25/24/25 | 26.97 | +0.94% |
| 24/24/24 | 26.72 | +3.93% |
| 21/24/21 | 25.71 | -0.08% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 06:14 pm IST
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| WKN | UL8NU2 |
| ISIN | CH1294696567 |
| Date issued | 07/09/2023 |
| Strike | 640 $ |
| Maturity | 20/12/2024 (176 Days) |
| Parity | 10 : 1 |
| Emission price | 4.86 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 27.7 € |
|---|---|
| Lowest since issue | 3.9 € |
| Delta | 0x |
| Omega | 0.000000 |
| Premium | 0x |
| Gearing | 0x |
| Moneyness | 1.408 |
| Difference Strike | -263.3 $ |
| Difference Strike % | -41.14% |
| Intrinsic value | 24.37 |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Warrants
- Warrant
